TC BIOPHARM HOLDINGS PLC-ADR (TCBP)

Company Profile

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The firm is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Its platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. Its pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications. The Company’s therapies are focused on leveraging the inherent biological capabilities of GDT cells together with an integrated cell engineering approach.

Company Info

TC BIOPHARM HOLDINGS PLC-ADR

Maxim 1, 2 Parklands Way

Honiton

Employees: 41

Website: https://tcbiopharm.com/